Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bortezomib + carmustine + etoposide + cytarabine + melphalan
- Development stage
- Phase 2
- Lead developer
- University of Nebraska
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Velcade-BEAM is an experimental conditioning regimen developed by the University of Nebraska Medical Center for patients undergoing autologous hematopoietic stem cell transplantation (ASCT). It combines the proteasome inhibitor bortezomib (Velcade) with the standard BEAM chemotherapy backbone, which consists of carmustine (BCNU), etoposide, cytarabine (Ara-C), and melphalan. Bortezomib targets the 26S proteasome, inhibiting the NF-κB pathway to sensitize lymphoma cells to the cytotoxic effects of the alkylating agents and antimetabolites in the BEAM regimen. This combination is primarily investigated for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma, transformed lymphoma, and mantle cell lymphoma, aiming to improve complete response rates and progression-free survival compared to BEAM alone.
- Other names
- Velcade-BEAMV-BEAMBortezomib-BEAMbortezomib + BEAMbortezomib + BCNU + etoposide + Ara-C + melphalan
02
Targets
PSMB5 (Proteasome subunit beta Type-5)DNADNA polymerase familyTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on bortezomib + carmustine + etoposide + cytarabine + melphalan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bortezomib + carmustine + etoposide + cytarabine + melphalan.